tbuckley/cabot-search huggingface dataset:
Patient found in contempt of court for trying to claim £837 000 from hospital trust
Authors: Clare Dyer
Journal: BMJ (2018)

A DJ and taxi driver has been found guilty of contempt of court for fraudulently claiming more than £837 000 (€950 000; $1.2m) in damages for clinical negligence after he was treated in a hospital emergency department.1 Sandip Singh Atwal, 33, is to be sentenced on 1 June, when he faces a possible prison term.

Insurers sometimes bring contempt of court proceedings over inflated claims, but the Atwal case is thought to be the first time the move has been used by the …
Omics of Blood Pressure and Hypertension
Authors: Donna K. Arnett, Steven A. Claas
Journal: Circulation Research (2018)

Essential hypertension is a common, complex disorder affecting ≤1 billion adults globally. Blood pressure is a highly heritable trait, with ≤50% of the variation between individuals accounted for by familial relationships. Despite this strong heritability, determining the genetic architecture of hypertension in humans has proved challenging. Recent technological and methodological developments have given rise to what is now known as omics-a domain of study that includes genomics, as well as epigenomics, transcriptomics, proteomics, and metabolomics. For complex traits like hypertension, which involve multiple pathways and organs, omic approaches offer the advantage of allowing identification of novel hypertensive mechanisms to help further dissect and characterize the disorder's pathophysiology. This review provides a primer on the genomics, transcriptomics, proteomics, and metabolomics of blood pressure and hypertension. We provide an introduction to each approach with examples chosen to illustrate its potential. We conclude with a brief assessment of current methods aimed at integrating multiomic data. A review of the literature found genomic, epigenomic, transcriptomic, proteomic, and metabolomic methods have been applied to dissect the pathophysiology of blood pressure and hypertension. Omic methods and integration of multiomic data represent a potentially fruitful approach to illuminating the complex pathophysiology of hypertension and, ultimately, may point to novel diagnostics and treatments.
Prognosis after abdominal surgery in patients with idiopathic non-cirrhotic portal hypertension: A multicenter retrospective study
Authors: L. Elkrief, J. Ferrusquia, P. Audrey, L. Moga, T. Luis, M. Praktiknjo, B. Procopet, R. Yuldashev, H. Geovanni, V. Hernandez-Gea, A. Albillos, J. Trebicka, L. Spahr, A. Plessier, D. Valla, L. Rubbia-Brandt, C. Toso, C. Bureau, G.P.J. Carlos, P.-E. Rautou
Journal: Journal of Hepatology (2018)
Hepatitis E virus replication and interferonresponse in human placental-derived cells
Authors: P. Behrendt, L. Knegendorf, S. Drave, K. Resner, D. Todt, M. Friesland, M. Engelmann, R. Brown, Y. Debing, V.L.D. Thi, H. Wedemeyer, J. Neyts, M.P. Manns, T. Pietschmann, E. Steinmann
Journal: Journal of Hepatology (2018)
Abstract 14289: Human Epididymis Protein 4 (HE4) and Outcome in Low-Flow, Low-Gradient Aortic Stenosis
Authors: Rami Abu-Alhayja’a, Abdellaziz Dahou, Marie-Annick Clavel, Lionel Tastet, Nancy Côté, Jonathan Beaudoin, Josep Rodés-Cabau, Brian Lindman, Philippe Pibarot
Journal: Circulation (2016)

Background:  Plasma level of Human Epididymis protein 4 (HE4) has been shown to be associated with increased risk of mortality in patients with heart failure. The objective of this study was to examine the prognostic value of HE4 in patients with low-flow, low-gradient aortic stenosis (LF-LG AS) with either preserved or reduced LVEF.   Methods:  Eighty patients (mean age: 73±10 year; 75% men) with LF-LG AS (LVEF  2 , mean gradient  2 ) prospectively enrolled in the True or Pseudo-severe Aortic Stenosis (TOPAS) study were included in this analysis. Forty-seven patients (58%) underwent aortic valve replacement (AVR) within 3 months following inclusion. The cohort was divided into two groups according to the median value of HE4 plasma levels (90 pmol/l). The primary endpoint was all-cause mortality.   Results:  Patients with higher HE4 plasma level were older and had lower LVEF (all p   Conclusion:  In patients with LF-LG AS, elevated HE4 plasma level was associated with higher risk of mortality even after adjustment for clinical risk, type of treatment, LV function, and natriuretic peptide level. This new biomarker may be useful to enhance risk stratification in LF-LG AS patients.
Phase I study of hepatic arterial infusion (HAI) therapy with floxuridine (FUDR) combined with systemic gemcitabine and oxaliplatin in patients with locally advanced intrahepatic cholangiocarcinoma (ICC).
Authors: Patrick Grierson, Aabha Oza, Maria Majella Doyle, Kathryn Fowler, Ryan Fields, William G. Hawkins, Chet Hammill, Andrea Wang-Gillam, Manik A. Amin, Katrina Pedersen, Kian-Huat Lim, Ashley Morton, Christine Cordova, Benjamin R. Tan, William C. Chapman
Journal: Journal of Clinical Oncology (2018)

417 Background: The standard of care for unresectable ICC is palliative systemic chemotherapy with cisplatin and gemcitabine. HAI therapy with FUDR in ICC resulted in high response rates [Kemeny 2011]. The use of HAI FUDR with systemic chemotherapy may improve outcomes. We conducted a phase 1 study of HAI FUDR with systemic gemcitabine and oxaliplatin. Methods: We enrolled patients in 3 cohorts: FUDR 0.16mg/kg/day x 14 days (Cohort 1), FUDR 0.12 mg/kg/day x 14 days with gemcitabine 1000mg/m2 on days 1, 8, 15 (Cohort 2), and FUDR 0.10 mg/kg/day x 14 days with gemcitabine 800mg/m2 days 1, 15 and oxaliplatin 85mg/m2 days 1, 15 (Cohort 3). The primary endpoint was the recommended phase 2 dose (RP2D) for Cohort 3. DLTs were assessed during cycle 1. Secondary objectives were response rate and survival. Results: We enrolled 24 patients, 6 male, age range 42-81 years (median 64). No DLTs were observed in Cohort 1 (FUDR). In Cohort 2 (FUDR + Gem), the addition of gemcitabine at 1000mg/m2 days 1, 8, 15 resulted in grade 3 LFT elevation in 2 patients; for subsequent patients, the gemcitabine dose was reduced to 800mg/m2, and no further DLT were noted. No DLT were observed in Cohort 3 (FUDR + GemOx). 10 patients experienced partial responses and conversion to resectable disease occurred in all cohorts. No other significant toxicities occurred. Conclusions: FUDR via HAI with systemic gemcitabine and oxaliplatin is well-tolerated in patients with unresectable cholangiocarcinoma, with a high rate of response and disease control, allowing for resection in some patients. Our RP2D is FUDR 0.10 mg/kg/day x 14 days, with gemcitabine 800mg/m2 days 1, 15 and oxaliplatin 85mg/m2 days 1, 15. Collaboration with MSKCC is ongoing. Clinical trial information: NCT01525069. [Table: see text]
AXL-expressing monocytes indicate immuneparesis and disease severity in patients with cirrhosis
Authors: R. Brenig, C. Perez, F.H.T. Duong, P. Kuenzler, L. Besse, S. Wieland, O. Pop, E. Triantafyllou, T. Boldanova, S. Brand, L. Terraciano, J. Wendon, M. Heim, D. Semela, H. Antoniades, C. Bernsmeier
Journal: Journal of Hepatology (2018)
Identification of keratin 19-positive cancer stem cells associating human hepatocellular carcinoma using 18F-FDGPET and CYFRA 21-1
Authors: T. Kawai, T. Ishii, K. Yasuchika, S. Seo, S. Ogiso, Y. Miyauchi, R. Yamaoka, H. Kojima, T. Minami, K. Fukumitsu, S. Uemoto
Journal: Journal of Hepatology (2018)
The Way We Walked with Immunology
Authors: Kimishige Ishizaka
Journal: Annual Review of Immunology (2018)

It has been a little more than 50 years since we discovered IgE, a key molecule for the allergic response and a target for treating allergies and severe asthma. Here, I trace my career, from the kindling of my interest in immunochemistry to groundbreaking discoveries in the biology and chemistry of immunoglobulins. I describe my service to the broader community of immunologists and my role in shaping departments and research institutes. My course starts in Japan and includes Southern California, Baltimore, and Denver.
The GSK3 Signaling Axis Regulates Adaptive Glutamine Metabolism in Lung Squamous Cell Carcinoma
Authors: Milica Momcilovic, Sean T. Bailey, Jason T. Lee, Michael C. Fishbein, Daniel Braas, James Go, Thomas G. Graeber, Francesco Parlati, Susan Demo, Rui Li, Tonya C. Walser, Michael Gricowski, Robert Shuman, Julio Ibarra, Deborah Fridman, Michael E. Phelps, Karam Badran, Maie St. John, Nicholas M. Bernthal, Noah Federman, Jane Yanagawa, Steven M. Dubinett, Saman Sadeghi, Heather R. Christofk, David B. Shackelford
Journal: Cancer Cell (2018)
Hip Fractures in Patients With Advanced Dementia
Authors: David R. Mehr, Paul E. Tatum, Brett D. Crist
Journal: JAMA Internal Medicine (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Safety, tolerability, and pharmacokinetics of BMS-986263/ND-L02-s0201, a novel targeted lipid nanoparticle delivering HSP47 siRNA, in healthy participants: A randomised, placebo-controlled, double-blind, phase 1 study
Authors: B. Soule, G. Tirucherai, U. Kavita, S. Kundu, R. Christian
Journal: Journal of Hepatology (2018)
Asia-Pacific working group consensus on non-variceal upper gastrointestinal bleeding: an update 2018
Authors: Joseph JY Sung, Philip WY Chiu, Francis K L Chan, James YW Lau, Khean-lee Goh, Lawrence HY Ho, Hwoon-young Jung, Jose D Sollano, Takuji Gotoda, Nageshwar Reddy, Rajvinder Singh, Kentaro Sugano, Kai-chun Wu, Chun-Yin Wu, David J Bjorkman, Dennis M Jensen, Ernst J Kuipers, Angel Lanas
Journal: Gut (2018)

Non-variceal upper gastrointestinal bleeding remains an important emergency condition, leading to significant morbidity and mortality. As endoscopic therapy is the ’gold standard' of management, treatment of these patients can be considered in three stages: pre-endoscopic treatment, endoscopic haemostasis and post-endoscopic management. Since publication of the Asia-Pacific consensus on non-variceal upper gastrointestinal bleeding (NVUGIB) 7 years ago, there have been significant advancements in the clinical management of patients in all three stages. These include pre-endoscopy risk stratification scores, blood and platelet transfusion, use of proton pump inhibitors; during endoscopy new haemostasis techniques (haemostatic powder spray and over-the-scope clips); and post-endoscopy management by second-look endoscopy and medication strategies. Emerging techniques, including capsule endoscopy and Doppler endoscopic probe in assessing adequacy of endoscopic therapy, and the pre-emptive use of angiographic embolisation, are attracting new attention. An emerging problem is the increasing use of dual antiplatelet agents and direct oral anticoagulants in patients with cardiac and cerebrovascular diseases. Guidelines on the discontinuation and then resumption of these agents in patients presenting with NVUGIB are very much needed. The Asia-Pacific Working Group examined recent evidence and recommends practical management guidelines in this updated consensus statement.
Data from the US and UK cystic fibrosis registries support disease modification by CFTR modulation with ivacaftor
Authors: Leona Bessonova, Nataliya Volkova, Mark Higgins, Leif Bengtsson, Simon Tian, Christopher Simard, Michael W Konstan, Gregory S Sawicki, Ase Sewall, Stephen Nyangoma, Alexander Elbert, Bruce C Marshall, Diana Bilton
Journal: Thorax (2018)

Background Ivacaftor is the first cystic fibrosis transmembrane conductance regulator (CFTR) modulator demonstrating clinical benefit in patients with cystic fibrosis (CF). As ivacaftor is intended for chronic, lifelong use, understanding long-term effects is important for patients and healthcare providers. Objective This ongoing, observational, postapproval safety study evaluates clinical outcomes and disease progression in ivacaftor-treated patients using data from the US and the UK CF registries following commercial availability. Methods Annual analyses compare ivacaftor-treated and untreated matched comparator patients for: risks of death, transplantation, hospitalisation, pulmonary exacerbation; prevalence of CF-related complications and microorganisms and lung function changes in a subset of patients who initiated ivacaftor in the first year of commercial availability. Results from the 2014 analyses (2 and 3 years following commercial availability in the UK and USA, respectively) are presented here. Results Analyses included 1256 ivacaftor-treated and 6200 comparator patients from the USA and 411 ivacaftor-treated and 2069 comparator patients from the UK. No new safety concerns were identified based on the evaluation of clinical outcomes included in the analyses. As part of safety evaluations, ivacaftor-treated US patients were observed to have significantly lower risks of death (0.6% vs 1.6%, p=0.0110), transplantation (0.2% vs 1.1%, p=0.0017), hospitalisation (27.5% vs 43.1%, p&lt;0.0001) and pulmonary exacerbation (27.8% vs 43.3%, p&lt;0.0001) relative to comparators; trends were similar in the UK. In both registries, ivacaftor-treated patients had a lower prevalence of CF-related complications and select microorganisms and had better preserved lung function. Conclusions While general limitations of observational research apply, analyses revealed favourable results for clinically important outcomes among ivacaftor-treated patients, adding to the growing body of literature supporting disease modification by CFTR modulation with ivacaftor. EU PAS registration number EUPAS4270
Diabetes-Attributable Nursing Home Costs for Each U.S. State
Authors: Simon J. Neuwahl, Amanda A. Honeycutt, Diana C. Poehler, Sundar S. Shrestha, Ping Zhang, Thomas J. Hoerger
Journal: Diabetes Care (2018)

OBJECTIVE To estimate the diabetes-attributable nursing home costs for each state. RESEARCH DESIGN AND METHODS We used a diabetes-attributable fraction (AF) approach to estimate nursing home costs attributable to diabetes (in 2013 dollars) in aggregate and per person with diabetes in each state. We calculated the AFs as the difference in diabetes prevalence between nursing homes and the community. We used the Centers for Medicare &amp; Medicaid Services 2013–2015 Minimum Data Set to estimate the prevalence of diabetes in nursing homes and to adjust for the intensity of care among people with diabetes in nursing homes. Community prevalence was estimated using the Behavioral Risk Factor Surveillance System (BRFSS). State nursing home expenditures were from the 2013 State Health Expenditure Accounts. RESULTS The fraction of total nursing home expenditures attributable to diabetes ranged from 12.3% (Illinois) to 22.5% (Washington, DC; median AF of 15.6%, New Jersey). The median AF was highest in the 19–64 years age-group and lowest in the 85 years or older age-group. Nationally, diabetes-attributable nursing home costs were $18.6 billion. State-level diabetes-attributable costs ranged from $21 million in Alaska to $2.0 billion in California. Diabetes-attributable nursing home costs per person ranged from $374 in New Mexico to $1,610 in Washington, DC (median of $799 in Maine). CONCLUSIONS Our estimates provide state policymakers with an improved understanding of the economic burden of diabetes in each state’s nursing homes. These estimates could serve as critical inputs for planning and evaluating diabetes prevention and management interventions that can keep people healthier and living longer in their communities.
A hepatic pDNA delivery system based on an intracellular environment sensitive vitamin E-scaffold lipid-like material with the aid of an anti-inflammatory drug
Authors: Ryohei Togashi, Hiroki Tanaka, Sakiko Nakamura, Hideo Yokota, Kota Tange, Yuta Nakai, Hiroki Yoshioka, Hideyoshi Harashima, Hidetaka Akita
Journal: Journal of Controlled Release (2018)
MEGA X: Molecular Evolutionary Genetics Analysis across Computing Platforms
Authors: Sudhir Kumar, Glen Stecher, Michael Li, Christina Knyaz, Koichiro Tamura
Journal: Molecular Biology and Evolution (2018)

The Molecular Evolutionary Genetics Analysis (Mega) software implements many analytical methods and tools for phylogenomics and phylomedicine. Here, we report a transformation of Mega to enable cross-platform use on Microsoft Windows and Linux operating systems. Mega X does not require virtualization or emulation software and provides a uniform user experience across platforms. Mega X has additionally been upgraded to use multiple computing cores for many molecular evolutionary analyses. Mega X is available in two interfaces (graphical and command line) and can be downloaded from www.megasoftware.net free of charge.
Non-coding RNAs in endometriosis: a narrative review
Authors: Kavita Panir, John E Schjenken, Sarah A Robertson, M Louise Hull
Journal: Human Reproduction Update (2018)

Endometriosis is a benign gynaecological disorder, which affects 10% of reproductive-aged women and is characterized by endometrial cells from the lining of the uterus being found outside the uterine cavity. However, the pathophysiological mechanisms causing the development of this heterogeneous disease remain enigmatic, and a lack of effective biomarkers necessitates surgical intervention for diagnosis. There is international recognition that accurate non-invasive diagnostic tests and more effective therapies are urgently needed. Non-coding RNA (ncRNA) molecules, which are important regulators of cellular function, have been implicated in many chronic conditions. In endometriosis, transcriptome profiling of tissue samples and functional in vivo and in vitro studies demonstrate that ncRNAs are key contributors to the disease process.In this review, we outline the biogenesis of various ncRNAs relevant to endometriosis and then summarize the evidence indicating their roles in regulatory pathways that govern disease establishment and progression.Articles from 2000 to 2016 were selected for relevance, validity and quality, from results obtained in PubMed, MEDLINE and Google Scholar using the following search terms: ncRNA and reproduction; ncRNA and endometriosis; miRNA and endometriosis; lncRNA and endometriosis; siRNA and endometriosis; endometriosis; endometrial; cervical; ovary; uterus; reproductive tract. All articles were independently screened for eligibility by the authors.This review integrates extensive information from all relevant published studies focusing on microRNAs, long ncRNAs and short inhibitory RNAs in endometriosis. We outline the biological function and synthesis of microRNAs, long ncRNAs and short inhibitory RNAs and provide detailed findings from human research as well as functional studies carried out both in vitro and in vivo, including animal models. Although variability in findings between individual studies exists, collectively, the extant literature justifies the conclusion that dysregulated ncRNAs are a significant element of the endometriosis condition.There is a compelling case that microRNAs, long non-coding RNAs and short inhibitory RNAs have the potential to influence endometriosis development and persistence through modulating inflammation, proliferation, angiogenesis and tissue remodelling. Rapid advances in ncRNA biomarker discovery and therapeutics relevant to endometriosis are emerging. Unravelling the significance of ncRNAs in endometriosis will pave the way for new diagnostic tests and identify new therapeutic targets and treatment approaches that have the potential to improve clinical options for women with this disabling condition.
Differential glucose requirement in skin homeostasis and injury identifies a therapeutic target for psoriasis
Authors: Zhuzhen Zhang, Zhenzhen Zi, Eunice E. Lee, Jiawei Zhao, Diana C. Contreras, Andrew P. South, E. Dale Abel, Benjamin F. Chong, Travis Vandergriff, Gregory A. Hosler, Philipp E. Scherer, Marcel Mettlen, Jeffrey C. Rathmell, Ralph J. DeBerardinis, Richard C. Wang
Journal: Nature Medicine (2018)
Index of Microcirculatory Resistance as a Tool to Characterize Microvascular Obstruction and to Predict Infarct Size Regression in Patients With STEMI Undergoing Primary PCI
Authors: Giovanni Luigi De Maria, Mohammad Alkhalil, Mathias Wolfrum, Gregor Fahrni, Alessandra Borlotti, Lisa Gaughran, Sam Dawkins, Jeremy P Langrish, Andrew J Lucking, Robin P Choudhury, Italo Porto, Filippo Crea, Erica Dall'Armellina, Keith M Channon, Rajesh K Kharbanda, Adrian P Banning
Journal: JACC. Cardiovascular imaging (2018)
Lysyl oxidase like-2 contributes to renal fibrosis in Col4α3/Alport mice
Authors: Dominic Cosgrove, Brianna Dufek, Daniel T. Meehan, Duane Delimont, Michael Hartnett, Gina Samuelson, Michael Anne Gratton, Grady Phillips, Deidre A. MacKenna, Gretchen Bain
Journal: Kidney International (2018)
Lipid-induced ASK1 activation in hepatocytes and Kupffer cells mediates the increased vulnerability of fatty liver to Ischemia/Reperfusion injury in mice
Authors: C. Imarisio, E. Alchera, C.B. Revanna, G. Valente, A. Follenzi, E. Trisolini, R. Boldorini, R. Carini
Journal: Journal of Hepatology (2018)
NAA25 and Tropomyosin regulate liver metabolic zonation, hepatocyte polarity and ploidy
Authors: L. Neri, V. Dominguez, J. Elurbide, M. Lasa, M. Ariz, A. Perez-Iturralde, B. Carte, L. Nicolas, E. Vicente, C.O. de Solorzano, A. Muñoz-Barrutia, B. Pintado, R. Aldabe
Journal: Journal of Hepatology (2018)
Evolution of glomerular filtration rates and neutrophil gelatinase-associated lipocalin during treatment with direct acting antivirals
Authors: Alessio Strazzulla, Giuseppe Coppolino, Giorgio Settimo Barreca, Innocenza Gentile, Laura Rivoli, Maria Concetta Postorino, Maria Mazzitelli, Giuseppe Greco, Chiara Costa, Vincenzo Pisani, Nadia Marascio, Mariadelina Simeoni, Alfredo Focà, Giorgio Fuiano, Daniela Foti, Elio Gulletta, Carlo Torti
Journal: Clinical and Molecular Hepatology (2018)

Correct renal function evaluation is based on estimated glomerular filtration rates (eGFR) and complementary renal damage biomarkers, such as neutrophil gelatinase associated lipocalin (NGAL). The aim of this study was to evaluate eGFR and NGAL modifications and renal impairment during treatment with a direct acting antiviral (DAA) for chronic hepatitis C virus (HCV) infection.A retrospective cohort study evaluated eGFR modification during treatment with DAA. Subgroup analysis on serum NGAL was conducted in those receiving sofosbuvir/ledipasvir, with complete follow-up until week 12 after the end of treatment (FU-12).In the 102 enrolled patients, eGFR reduction was observed (from 86.22 mL/min at baseline to 84.43 mL/min at FU-12, P=0.049). Mean NGAL increased in 18 patients (from 121.89 ng/mL at baseline to 204.13 ng/mL at FU-12, P=0.014). At FU-12, 38.8% (7/18) of patients had a plasmatic NGAL value higher than the normal range (36-203 ng/mL) compared with 11.1% (2/18) at baseline (χ 2 =3,704; P=0.054). In contrast, eGFR did not change significantly over the follow-up in this subgroup.In conclusion, compared to a negligible eGFR decline observed in the entire cohort analyzed, a significant NGAL increase was observed after HCV treatment with DAA in a small subgroup. This could reflect tubular damage during DAA treatment rather than glomerular injury.